William Blair Weighs in on Zevra Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at William Blair upped their Q3 2024 earnings estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, August 14th. William Blair analyst T. Lugo now anticipates that the company will post earnings of ($0.42) per share for the quarter, up from their prior forecast of ($0.44). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.57) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.58) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.70) EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright upped their price objective on shares of Zevra Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research report on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $20.25.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $7.37 on Friday. The stock has a market capitalization of $308.46 million, a price-to-earnings ratio of -5.46 and a beta of 1.97. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.44. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.88. The firm has a fifty day simple moving average of $5.69 and a 200-day simple moving average of $5.52.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The company had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. During the same period last year, the business earned ($0.15) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in ZVRA. International Assets Investment Management LLC boosted its holdings in Zevra Therapeutics by 555.0% in the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after acquiring an additional 5,550 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics during the first quarter valued at about $64,000. The Manufacturers Life Insurance Company increased its holdings in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. IFG Advisors LLC lifted its holdings in shares of Zevra Therapeutics by 45.0% in the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock valued at $108,000 after purchasing an additional 5,800 shares in the last quarter. Finally, Strs Ohio lifted its stake in Zevra Therapeutics by 151.9% during the 4th quarter. Strs Ohio now owns 19,400 shares of the company’s stock valued at $127,000 after acquiring an additional 11,700 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Thomas Anderson acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were purchased at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now directly owns 20,000 shares in the company, valued at $136,200. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders bought a total of 22,000 shares of company stock valued at $140,340 in the last quarter. Company insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.